Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium -- Ignore unavailable to you. Want to Upgrade?

To: swisstrader who wrote (85450)	3/14/2000 9:51:00 AM
From: Tassi	Respond to of 108040

AVAN.. NEEDHAM, Mass, March 14 (Reuters) - Avant Immunotherapeutics Inc. AVAN.O said Tuesday that the U.S. Food and Drug Administration has granted orphan drug status for its TP10 to improve post-operative outcomes in infants undergoing cardiac surgery. Orphan drug status provides U.S. marketing exclusivity for seven years following the drug's marketing approval by the FDA; the status also provides tax benefits. Avant said it expects to report results from its Phase 1/11 safety and efficacy trials during the second quarter and begin pivotal Phase III trials in infants undergoing cardiac surgery by the end of the year. About 15,000 infants in the United States undergo cardiac surgery to correct congenital heart defects each year. REUTERS Rtr 09:09 03-14-00